Akari Therapeutics Plc (AKTX)
About Akari Therapeutics Plc
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads utilizing powerful biology to attack cancer. Its payload, PH1, targets RNA splicing by modulating the spliceosome, a complex machinery in the cell that converts pre-RNA into spliced RNA for translation into vital proteins for cell survival and growth. Its product pipeline is AKTX-101, which targets the Trop2 receptor on cancer cells and, with a proprietary linker, enables it to deliver its novel PH1 payload directly into the tumor with minimal off-target effects. and AKTX-102, an ADC candidate targeting CEACAM5 (Carcinoembryonic Antigen-related Cell Adhesion Molecule-5), a well-validated tumor antigen expressed across multiple solid tumors.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2023
- $367.9K
- Net income
- -$17.3M
- Total assets
- $47.9M
- Market cap
- $17.2M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $17.3M
- Operating income
- -$17.3M
- Net income
- -$17.3M
- EPS (basic)
- $0.00
- EPS (diluted)
- $0.00
Balance sheet
- Total assets
- $47.9M
- Current assets
- $5.5M
- Total liabilities
- $19.6M
- Current liabilities
- $12.4M
- Shareholders’ equity
- $28.3M
Cash flow
- Operating cash flow
- -$10.6M
- Investing cash flow
- -$2.6M
- Financing cash flow
- $13.2M
- Net cash flow
- -$1.0K
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $17.2M
- Shares outstanding
- 2.0M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 7, 2012
Akari Therapeutics Plc (AKTX) Stock Price
- Reported a net loss of $17.3M in FY2023.
- Trading 81% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Akari Therapeutics Plc.
Write a review
News about Akari Therapeutics Plc
News & sentiment via Polygon.io
Akari Therapeutics Plc: frequently asked questions
Is Akari Therapeutics Plc an American company?
Akari Therapeutics Plc is a US-based company headquartered in Tampa, Florida, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Akari Therapeutics Plc headquartered?
Akari Therapeutics Plc is headquartered in Tampa, Florida, United States.
Is Akari Therapeutics Plc publicly traded?
Yes — Akari Therapeutics Plc is a publicly traded company. Its stock trades under the ticker symbol AKTX on the NASDAQ.
What does Akari Therapeutics Plc do?
Akari Therapeutics Plc is an American Pharmaceuticals company in the Health & Beauty sector.
